Stocks · Korea 308430 KOSDAQ

Cellbion

14,160원 -0.35% Market cap 1,827억 2026-10-07 close

📈 Chart & live quote

Data as of 2026-10-07 · Linked from 6 pages

An overview for this page is not available in English yet. The figures below are updated daily.

Key figures 2026-10-07 basis

PER—

PBR7.97x

EPS0 KRW

BPS1,776 KRW

ROE-41.53%

Dividend yield0.00%

DPS0 KRW

Payout ratio—

Returns and 52-week range

1W-4.71%

1M+17.90%

3M-17.14%

6M-56.96%

1Y-23.99%

YTD-36.07%

52W high42,200원

52W low9,930원

From 52W high-66.45%

Financial results (separate)

Period	Revenue	Operating income	Net income	OP margin
2024	23억	-71억	-73억	-311.7%
2025	19억	-82억	-76억	-423.9%
Quarterly
2024 3Q	12억	-17억	-17억	-146.7%
2025 1Q	5억	-17억	-14억	-344.4%
2025 2Q	4억	-21억	-19억	-515.3%
2025 3Q	7억	-20억	-18억	-294.1%
2025 4Q	4억	-25억	-24억	-657.6%
2026 1Q	6억	-24억	-24억	-398.9%

Company

CEO김권

Founded2010-07-21

Fiscal year end12

Websitecellbion.co.kr

Address: 서울특별시 종로구 대학로 103 서울대학교 암연구소 6층

Peers in the same sector

Company	Market cap	P/E	P/B	1M
대원제약	1,850억	—	0.66	+3.25%
나이벡	1,827억	38.63	3.99	+6.42%
삼일제약	1,850억	—	1.36	+40.30%
바이오솔루션	1,752억	614.55	5.11	+10.69%
종근당홀딩스	1,881억	4.42	0.28	-3.47%
JW생명과학	1,732억	5.92	0.77	-2.32%

Recent filings

2026-08-13반기보고서 (2026.06)
2026-05-14분기보고서 (2026.03)
2026-04-22[기재정정]주요사항보고서(유상증자결정) Major
2026-04-22[기재정정]주요사항보고서(전환사채권발행결정) Major
2026-04-15주요사항보고서(전환사채권발행결정) Major
2026-04-15주요사항보고서(유상증자결정) Major

Source: DART (Financial Supervisory Service electronic disclosure)

Sources and notes

This page summarizes public filings, market data and news for information only. It is not a recommendation to buy or sell any security. Figures are as of the dates shown; check the original filings before making decisions.